Lineage Cell Therapeutics, Inc. (LCTX)
XASE:LCTX
Want to see LCTX full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.02Last Year’s EPS
-0.13Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed substantial scientific and operational progress across Lineage's manufacturing platform and pipeline: AlloSCOPE advances, the launch and initial preclinical success of COR1, ILT1 scale-up milestones, completed engineering runs for ReSonance, device performance and site expansion for OPC1, SAB and clinical leadership hires, and partner validation for OpRegen (including multi-year vision durability and expansion to 17 sites). Financials show modest revenue, rising R&D and operating expenses, and a larger net loss year-over-year, but a cash runway into 2028 plus potential warrant proceeds and sizeable contingent Roche/Genentech milestones mitigate near-term funding concerns. Program risks remain — notably islet scale-up technical challenges, timing uncertainty tied to partners (OpRegen), and some earlier-stage setbacks (photoreceptor IP change, CIRM non-award) — however the volume and quality of operational and scientific milestones reported suggest progress materially outweighs current financial and program risks.Company Guidance
AlloSCOPE Manufacturing Platform Expansion
Successful expansion of the AlloSCOPE platform with two-tiered banking (master → working → clinical) demonstrated reproducible steps and FDA-cleared final product; company cites mathematical potential for millions of vials and cost-per-dose potentially in the hundreds of dollars, supporting allogeneic off-the-shelf strategies.
Launch of COR1 Corneal Endothelial Cell Program
Launched COR1 (wholly owned) for corneal endothelial disease (Fuchs and other dystrophies); preclinical development produced cryopreservable off-the-shelf corneal endothelial cells that met initial internal identity, morphology and functional criteria and will proceed to translational models with the goal of IND-enabling work.
OpRegen Partner Momentum and Long-term Data
Roche/Genentech analysis showed vision gains persisted at least 3 years after single administration in some patients; partner recently opened 11 new clinical sites (bringing GAlette study to 17 sites), indicating increased partner investment and operational scale for OpRegen.
ILT1 Manufacturing Milestone
Met first internal milestone for ILT1 by demonstrating a highly homogenized, scalable, fully suspension-based process for undifferentiated pluripotent cells at 0.5-liter scale and progressed into larger multi-liter formats to address islet-scale feedstock requirements.
OPC1 Delivery Device and Clinical Progress
DOSED trial (OPC1 delivery device) has performed as expected with no unexpected procedure/product/device-related adverse events or significant design changes; study expanded to a second site (Rancho Research Institute) and the first chronic SCI participant is approaching 1-year follow-up.
ReSonance Partnership and Manufacturing Runs
ReSonance (auditory neuronal cell program) partnership with William Demant: completed 3 engineering runs and preparing for GMP manufacturing; Demant committed up to $12M to preclinical activities (approx. two-thirds as reimbursement to Lineage).
Strategic SAB Appointment and Clinical Leadership Hire
Formed Scientific Advisory Board with founding member Dr. Joachim Froebus and hired Dr. Priyantha Harath as SVP & Head of Clinical — strengthening late-stage development, regulatory, and clinical execution capabilities.
Cash Position and Potential Near-Term Funding
Cash of $53.4M as of 03/31/2026, expected to fund operations into 2028; potential additional liquidity includes ~ $32M from existing warrants (contingent/accelerated on OpRegen advancement disclosure) and eligibility for up to $615M of Roche-Genentech milestone payments under collaboration.
LCTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LCTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2026 | $1.33 | $1.28 | -3.76% |
Mar 05, 2026 | $1.84 | $1.85 | +0.54% |
Nov 06, 2025 | $1.73 | $1.76 | +1.73% |
Aug 12, 2025 | $1.01 | $1.03 | +1.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Lineage Cell Therapeutics, Inc. (LCTX) report earnings?
Lineage Cell Therapeutics, Inc. (LCTX) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Lineage Cell Therapeutics, Inc. (LCTX) earnings time?
Lineage Cell Therapeutics, Inc. (LCTX) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LCTX EPS forecast?
LCTX EPS forecast for the fiscal quarter 2026 (Q2) is -0.02.